38th week of 2008 patent applcation highlights part 50 |
Patent application number | Title | Published |
20080227673 | Tribotechnical Lubricant and Lubricant Composition - The tribotechnical lubricant and lubricant composition may be used for friction decrease in friction units of machinery and equipments included heavy-loaded ones in aging and operation process. The tribotechnical lubricant contains x-ray amorphous carbon characterized by particle size by electron microscopy of 30 50 nm, temperature of oxidation beginning in air is not more than 300° C., nonconjugated double bonds concentration determinated on interaction with neutral potassium permanganate solution is not less than one per 5 carbon atoms, paramagnetic centers concentration on ESR-line with g factor 2,022 is not less than one per 1200 carbon atoms. The lubricant composition contains a base oil and x-ray amorphous carbon. | 2008-09-18 |
20080227674 | METHOD FOR REGENERATING LUBE OIL DISPERSANT - A method of regenerating used dispersant incorporated into lubricating oil is provided. The method comprises the steps of supplying used lubricating oil having dispersant molecules suspending particulate matter into a regenerating chamber; releasing the particulate matter by creating a stress on the bond between the dispersant molecules and the suspended particulate matter; permitting the released particulate matter to agglomerate; removing the agglomerated particulate matter from the lubricating oil; and discharging the lubricating oil back to the engine. An alternative method comprises the steps of supplying used lubricating oil having non-metallic polymer dispersant molecules suspending particulate matter into a capturing chamber, the dispersant molecules having polar ends and non-polar tails; interacting the used lubricating oil with an oil-insoluble capturing composition having a binding affinity for the particulate matter that is greater than that of the polar ends of the dispersant molecules to displace the suspended particulate matter and bind the particulate matter to the capturing composition within the capturing chamber; and discharging the lubricating oil back to the engine. | 2008-09-18 |
20080227675 | Near Anhydrous Consumer Products Comprising Fragranced Aminoplast Capsules - A liquid substantially non-aqueous cleaning or conditioning composition containing a surfactant or a conditioning active ingredient, a content in water which is not above 10% by weight, relative to the total weight of the composition, and a fragrance encapsulated in aminoplast type microcapsules. The compositions of the invention, in the form of fabric detergents or softeners, are particularly stable during storage and have an improved olfactive impact on fabrics. | 2008-09-18 |
20080227676 | Amine reaction compounds comprising one or more active ingredient - The present invention relates to a product of reaction between a primary and/or secondary amine and one or more active ingredients. By the present invention, there is provided a release of the active component over a longer period of time than by the use of the active itself. | 2008-09-18 |
20080227677 | Hand cleansing formulation - This invention provides heavy-duty cleansers (HDHC), with a high level of biodegradability and little or no ecotoxicity, with a high level of efficiency and a maximum skin tolerance and no systemic toxicity. In the broadest aspect of the invention there is provided a cleansing formulation comprising 5 to 10% of one or more methylesters of vegetable saturated and/or unsaturated fatty acids which may be from several natural sources including sunflower seed oil, soybean oil, rape seed oil, or coconut oil. The formulation includes between about 10% to 30% of one or more surfactants and a preferred combination of surfactants includes at least one ethoxylated fatty alcohol, one alkyl polyoxyethylene glycol, one alkanolamide and one polymeric quaternary ammonium salt. | 2008-09-18 |
20080227678 | Cleaning Liquid for Lithography and Method of Cleaning Therewith - A cleaning liquid for lithography that exhibits equally excellent cleaning performance for resists of a wide variety of compositions, such as various resists for i-line, KrF and ArF, silicic resist and chemical amplification type positive resist, and that excels in post-treatment dryability, being free from any deterioration of resist performance by cleaning. There is provided a cleaning liquid for lithography, comprising at least one member (A) selected from among lower alkyl esters of acetic acid and propionic acid and at least one member (B) selected from among ketones having 5 to 7 carbon atoms per molecule in a mass ratio of (A):(B) of 4:6 to 7:3. | 2008-09-18 |
20080227679 | Biodegradable Cleaning Compositions - The present invention is related to readily biodegradable cleaning compositions, methods of use, and manufacture thereof. The cleaning composition comprises a non-ionic surfactant and an amidoalkyl quaternary salt. | 2008-09-18 |
20080227680 | AQUEOUS OZONE SOLUTION FOR OZONE CLEANING SYSTEM - A method of making an aqueous ozone solution for an industrial cleaning system is described. The method includes providing a reaction vessel for entraining ozone gas in an aqueous solution. The reaction vessel includes a conical-shaped surface having a two or more edges or ridges. The conical-shaped surface defines an interior, and two or more edges or ridges are in contact with the interior. The reaction vessel is in fluidic communication with a supply of water. The reaction vessel is in fluidic communication with a supply of a first aqueous ozone solution. The first aqueous ozone solution is directed to the conical-shaped surface. Water is directed to the conical-shaped surface, and the water and the first aqueous ozone solution are mixed to form a second aqueous ozone solution. | 2008-09-18 |
20080227681 | COLLOIDAL CLEANING SYSTEM - Cleaning formulations, methods, and systems are effective, mild, and non-hazardous. Embodiments of the cleaning formulation comprise a fatty acid, a saponifier, a water conditioner, a solvent, a nonionic surfactant, and an anionic surfactant. Some embodiments also optionally additives. Embodiments are particularly effective for cleaning concrete. | 2008-09-18 |
20080227682 | Acidic Hard Surface Cleaning Compositions - The present invention is directed to an acidic hard surface treatment composition which provides a cleaning benefit comprising: an acidic constituent which comprises water soluble organic acid; at least one anionic surfactant constituent; at least one nonionic surfactant constituent; at least one organic solvent constituent; at least one inorganic chloride salt; optionally one or more further constituents and the balance, water. | 2008-09-18 |
20080227683 | Compounds Having Antitumor Activity - Disclosed is the use of compounds of formula (I) wherein X, Y and Z are as defined in the description of the invention, for the preparation of an antitumor medicament, optionally in combination with different biologically active substances. | 2008-09-18 |
20080227684 | Small Molecule Inhibitors of PDZ Interactions - The present invention relates to compositions for use in the modulation of PDZ domain interactions with cognate ligands. Methods of assessing and characterizing PDZ domain interactions from various polypeptides also are provided. | 2008-09-18 |
20080227685 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS - The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation (post-operative ileus), and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor. | 2008-09-18 |
20080227686 | Novel Peptides that Promote Lipid Efflux - Disclosed herein are peptides with domains that promote lipid efflux from cells and optionally possess at least one anti-inflammatory domain or a domain that stimulates LCAT activity. Provided herein are methods of using the peptides to treat or inhibit diseases including dyslipidemic disorders, stroke and myocardial infarction. Also provided are methods of detecting plaque in vessels using the labeled peptides of the present invention. | 2008-09-18 |
20080227687 | COMPOSITION AND METHOD FOR CANCER TREATMENT USING TARGETED SINGLE-WALLED CARBON NANOTUBES - The present invention is a method for detecting and destroying cancer tumors. The method is based on the concept of associating a linking protein or linking peptide such as, but not limited to, annexin V or other annexins to single-walled carbon nanotubes (SWNT) to form a protein-SWNT complex. Said linking protein or peptide can selectively bind to cancerous cells, especially tumor vasculature endothelial cells, rather than to healthy ones by binding to cancer-specific external receptors such as anionic phospholipids including phosphatidylserine expressed on the outer surfaces of cancer cells only. Irradiation of bound SWNTs with specific wavelength is then used to detect and destroy those cells to which the SWNTs are bound via the linking protein or peptide thereby destroying the tumor or cancer cells. | 2008-09-18 |
20080227688 | Inhibition of viral replication - The present invention provides inhibitors of viral replication, and methods related thereto. In general, such compounds can be classified as peptidyl fluoromethylketones (PFMKs). The PFMK compounds may be used to partially or completely inhibit viral infection. In certain embodiments, Z-FA-FMK may be used to inhibit replication of a reovirus, such as a wild-type or attenuated reovirus, or a leporipoxvirus, such as myxoma virus. These compounds may be useful for controlling viral infectivity in vivo and/or in vitro. | 2008-09-18 |
20080227689 | Dampening Humoral and Innate Immunity by Inhibition of Ppgalnact-1 - The invention provides methods and compositions for treating pathogenic immune and inflammatory disorders through inhibition of polypeptide GalNAc transferase 1 (ppGalNAcT-1) transferase activity. | 2008-09-18 |
20080227690 | PARTICLES FOR INHALATION HAVING RAPID RELEASE PROPERTIES - The invention generally relates to formulations having particles comprising phospholipids, bioactive agent and excipients and the pulmonary delivery thereof. Dry powder inhaled insulin formulations are disclosed. Formulations comprising DPPC, insulin and sodium citrate which are useful in the treatment of diabetes are disclosed. Also, the invention relates to a method of for the pulmonary delivery of a bioactive agent comprising administering to the respiratory tract of a patient in need of treatment, or diagnosis an effective amount of particles comprising a bioactive agent or any combination thereof in association, wherein release of the agent from the administered particles occurs in a rapid fashion. | 2008-09-18 |
20080227691 | Blood Coagulation FVIII Analogues - The invention is related to a FVIII analogue which has a circulation time in the blood stream before activation of at least about two times of that of native FVIII and a week after injection to a patient retains at least about 5% of the FVIII activity compared to the initial activity peak value reached after injection. The claimed FVIII analogues comprise a targeted disruption of one or more of the clearance sites in the FVIII molecule by introduction of at least one N-glycosylation site or by introduction of at least one Cys residue within or spatially close to the clearance site in the A2 domain or a combination thereof. The inserted cysteine residues may be further modified by conjugation with a chemical group increasing the molecular weight of the FVIII analogue. | 2008-09-18 |
20080227692 | Compositions and methods for treating ophthalmic disorders - The present invention relates to compositions and methods for treating and/or preventing ocular disorders, diseases or conditions and compositions and methods for treating or preventing ophthalmic conditions and disorders in a subject in need thereof. | 2008-09-18 |
20080227693 | Cyclic Peptide Isolation by Spray Drying - Methods for isolation of a synthetic cyclic peptide by spray drying, including spray drying at elevated temperatures, products made by the methods, and synthetic cyclic peptides preparations with defined characteristics, including an essentially amorphous acid addition salt of Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH in the form of a fine powder with a particle diameter of about 2 to about 20 microns. | 2008-09-18 |
20080227694 | Novel Interaction Between Proteins, and Therapeutic Agent for Disuse Muscular Atrophy or Method Associated with Disuse Muscular Atrophy Taking Advantage of Novel Interaction - [Problem] Providing a novel interaction between proteins. | 2008-09-18 |
20080227695 | Sfrp Expression Enhancing Agent - Tumor formation and reduced transcription of both sFRP1 gene and sFRP2 gene were found in Dlg gene knock-out mice, and thereby the following has been provided: an agent for enhancing the expression and/or function of sFRP, containing a compound having an effect of enhancing the expression and/or function of Dlg; an agent for inhibiting tumor formation or an agent for preventing and/or treating a tumor disease, containing the agent for enhancing the expression and/or function of sFRP; a method of enhancing the expression and/or function of sFRP, comprising enhancing the expression and/or function of Dlg; a method of inhibiting tumor formation or a method of preventing and/or treating a tumor disease, comprising using the aforementioned enhancing agent or the aforementioned enhancing method; a non-human mammal that is deficient in one or both of Dlg alleles; a cell originating in the mammal; a method of identifying a compound, comprising using the mammal or the cell; and a method of examining a tumor tissue or a tumor cell, comprising measuring the expression and/or function of Dlg. | 2008-09-18 |
20080227696 | Single branch heparin-binding growth factor analogs - A heparin-binding growth factor (HBGF) analog having two substantially similar sequences (homodimeric sequences) branched from a single amino acid residue, where the sequences are analogs of a particular HBGF that binds to a heparin-binding growth factor receptor (HBGFR), or alternatively that bind to a HBGFR without being an analog of any particular HBGF. The homodimeric sequences may be derived from any portion of a HBGF. The synthetic HBGF analog may be an analog of a hormone, a cytokine, a lymphokine, a chemokine or an interleukin, and may bind to any HBGFR. Further provided are preparations for medical devices, pharmaceutical compositions and methods of using the same. | 2008-09-18 |
20080227697 | Bacterial protein phosphoinositide probes and effectors - Methods for detecting and quantifying phosphoinositide lipids in a sample are provided, together with novel SidC- and SdcA-derived polypeptide fragments, or fusion proteins comprising such fragments that may be effectively employed as PI(4)P probes in biochemical and cell biological assays. Applications of the disclosed probes include: (i) detection and quantification of PI(4)P in vitro; and (ii) staining of intracellular compartments in live or fixed eukaryotic cells. | 2008-09-18 |
20080227698 | OLIGOPEPTIDES FOR TREATMENT OF OSTEOPOROSIS AND OTHER BONE DISEASES AND METHODS THEREOF - Oligopeptides which can be used to treat bone disease such as osteoporosis are disclosed. Further disclosed are methods of treating bone disease such as osteoporosis. These methods include administration of a polypeptide encoded by the Mesd gene, or an oligopeptide comprising a contiguous subsequence of a Mesd polypeptide. | 2008-09-18 |
20080227699 | Therapeutic Agent for Neurodegenerative Diseases - The present invention relates to a pharmaceutical composition for the treatment and/or prevention of a neurodegenerative disease, comprising the following polypeptide shown in any of (a) to (c): (a) a polypeptide comprising the amino acid sequence represented by Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala-Pro-Ala-Gly-Ala-Ser-Arg-Leu-Leu-Leu-Leu-Thr-Gly-Glu-Ile-Asp-Leu-Pro (SEQ ID NO: 1); (b) a polypeptide comprising an amino acid sequence having a deletion, substitution, insertion, and/or addition of one or several amino acids in the amino acid sequence consisting of Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala-Pro-Ala-Gly-Ala-Ser-Arg-Leu-Leu-Leu-Leu-Thr-Gly-Glu-Ile-Asp-Leu-Pro (SEQ ID NO: 1), and having an activity that inhibits neuronal cell death associated with neurodegenerative disease; and (c) a modified polypeptide from the polypeptide (a) or (b), or a pharmaceutically acceptable salt thereof, as an effective ingredient. | 2008-09-18 |
20080227700 | Compositions and Methods for Treatment of Protein Misfolding and Protein Aggregation Diseases - Small molecular weight molecules are provided including, but not limited to, peptides, peptide analogs and peptide mimetics that stabilize and prevent the aggregation of abnormally folded and compromised proteins. Methods for treatment of disease are provided utilizing the peptides, peptide analogs or peptide mimetics, or utilizing nucleic acids encoding the peptides. | 2008-09-18 |
20080227701 | ANTIANGIOGENIC POLYPEPTIDES AND METHODS FOR INHIBITING ANGIOGENESIS - Conjugated kringle protein fragments are disclosed as compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed. | 2008-09-18 |
20080227702 | Repair of larynx, trachea, and other fibrocartilaginous tissues - Provided herein are methods and devices for inducing the formation of functional replacement nonarticular cartilage tissues and ligament tissues. These methods and devices involve the use of osteogenic proteins, and are useful in repairing defects in the larynx, trachea, interarticular menisci intervertebral discs, ear, nose, ribs and other fibrocartilaginous tissues in a mammal. | 2008-09-18 |
20080227703 | Novel Neurotrophic Factors - The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same. | 2008-09-18 |
20080227704 | CXCL13 binding proteins - The present invention encompasses CXCL13 binding proteins. Specifically, the invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for CXCL13 and CXCL13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting mouse CXCL13 and for inhibiting mouse CXCL13 activity, e.g., in a mammal suffering from a disorder in which CXCL13 activity is detrimental. | 2008-09-18 |
20080227705 | Apoptosis-inducing agent and method for inducing apoptosis - An object of the present invention is to provide a novel means for stably and surely inducing cell apoptosis using the c-myc gene as a target. The present invention relates to an apoptosis-inducing agent containing a protein that interacts with an FBP protein or a polynucleotide encoding the protein as an active ingredient and a method for inducing apoptosis, which comprises a step of causing the apoptosis-inducing agent to come into contact with cells. | 2008-09-18 |
20080227706 | BVH-A2 AND BVH-A3 ANTIGENS OF GROUP B STREPTOCOCCUS | 2008-09-18 |
20080227707 | BIOACTIVE PEPTIDES AND UNIQUE IRES ELEMENTS FROM MYELIN PROTEOLIPID PROTEIN PLP/DM20 - Three novel low molecular weight (LMW) polypeptide fragments of a proteolipid protein human PLP/DM20 are designated PIRP-M, PIRP-L and PIRP-J, and are growth factors for oligodendrocytes with anti-apoptotic activity. They are encoded by mRNA from an IRES. Fusion polypeptides of such a LMW polypeptide, DNA encoding the LMW polypeptide and fusion polypeptide, expression vectors comprising such DNA, and cells expressing such polypeptides, or pharmaceutical compositions thereof, are useful for stimulating neural stem cell differentiation, maturation along the oligodendrocytic pathway and proliferation of oligodendrocytes or precursors. These compositions can protect oligodendrocytes (and nonneural cells) from apoptotic death. Thus, the present composition is used to treat a disease or condition in which such differentiation, maturation and proliferation or inhibition of cell death, including remyelination or stimulation of oligodendroglia or Schwann cells, is desirable. Disorders include multiple sclerosis, trauma with Parkinson's-like symptoms, hypoxic ischerriia and spinal cord trauma. | 2008-09-18 |
20080227708 | Methods Of Attenuating Prostate Tumor Growth By Insulin-Like Growth Factor Binding Protein-3 (IGFBP-3) - Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) inhibits cell growth and promotes apoptosis by sequestering free Insulin-like Growth Factor (IGF), and also demonstrates IGF-independent, pro-apoptotic, anti-proliferative effects on prostate cancer cells. Prostate tumor size was significantly attenuated in transgenic mice over-expressing IGFBP-3 compared with wild-type mice. In addition, a marked reduction in late-stage tumor growth was apparent in transgenic mice over expressing mutant-IGFBP-3 indicating that the IGF-independent effects of IGFBP-3 are related to inhibiting tumor progression. | 2008-09-18 |
20080227709 | GENE EXPRESSION IN PERIPHERAL BLOOD MONONUCLEAR CELLS FROM CHILDREN WITH DIABETES - The present invention includes composition, methods and systems for detecting, evaluating, diagnosis, tracking and treating Type 1 Diabetes by determining the level of expression of one or more genes listed in Table 1 (e.g., interleukin-1β (IL1B), early growth response gene 3 (EGR3), and prostaglandin-endoperoxide synthase 2 (PTGS2)). The present invention also includes compositions and methods for treating a patient in need thereof with a composition having a therapeutically effective amount of one or more IL-1β antagonists sufficient to spare pancreatic beta cells, including an anti-IL-1β receptor and downstream activators. | 2008-09-18 |
20080227710 | Use of Conjugates of Doxorubicin with Lactosaminated Albumin - The present invention refers to the use of a conjugate of doxorubicin with lactosaminated human albumin for the preparation of a pharmaceutical composition useful in the treatment of hepatocellular carcinomas (HCCs) which do not express the asialoglycoprotein receptor (ASGP-R). The conjugate which was previously prepared and studied only for the treatment of HCCs expressing the ASGP-R, has now been shown to possess the potentiality of a beneficial use also in the treatment of the HCCs which do not have the receptor. Therefore, compositions containing the conjugate could be administered for treatment of all HCCs, without the need of a preliminary tumor biopsy to demonstrate the presence or the absence of the receptor. | 2008-09-18 |
20080227711 | Cxc-Chemokine Antagonists - A novel CXC-chemokine binding protein is cloned from the salivary glands of | 2008-09-18 |
20080227712 | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides - The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted stem cell growth factor-like polypeptides. Other aspects of the invention include vectors containing processes for producing novel human secreted stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides. | 2008-09-18 |
20080227713 | Oxidized Human Bnp - The invention disclosed herein relates to oxidized forms of brain natriuretic peptide (BNP), particularly human BNP (hBNP). The disclosed invention relates to oxidized forms of B-type natriuretic peptide (BNP), which is useful as a marker for cardiovascular disease | 2008-09-18 |
20080227714 | Human Tumor Necrosis Factor TR18 and Methods Based Thereon - The present invention relates to TR18 polypeptides. In particular, isolated nucleic acid molecules are provided encoding human TR18 protein. TR18 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR18 activity. The invention further relates to methods of treating, preventing, prognosing, or diagnosing an autoimmune disease or condition associated with an autoimmune disease, comprising administering to a patient an effective amount of polypeptides of the invention. | 2008-09-18 |
20080227715 | Liquid composition of factor VII polypeptides - The invention concerns a liquid aqueous composition comprising (i) a factor VII polypeptide, (ii) an agent suitable for keeping pH in the range of from about 4.0 to about 9.0; (iii) an agent selected from the group consisting of: a calcium salt, a magnesium salt, or a mixture thereof; wherein the concentration of (iii) is less than 15 mM; and (iv) An ionic strength modifying agent; wherein the ionic strength of the composition is at least 200 mM. | 2008-09-18 |
20080227716 | Use of Peptides for Protecting Skin from Hair-Treatment Agents - The present invention relates to the use of short-chain peptides for the protection of the skin from hair-treatment agents, and particularly for the protection of the scalp from dyes or colorants. | 2008-09-18 |
20080227717 | Potent compstatin analogs - Compounds comprising peptides and peptidomimetics capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds. | 2008-09-18 |
20080227718 | PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE - The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of Aβ and antibodies binding to the same. | 2008-09-18 |
20080227719 | PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE - The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of Aβ and antibodies binding to the same. | 2008-09-18 |
20080227720 | Tumor cytotoxicity induced by modulators of the CXCR4 receptor - The present invention provides a means of selectively killing epithelial cell carcinomas by administering a CXCR4-specific sequence of the Gp120 protein or Nef proteins or the proteins themselves (the modulators) such as that found in strains HIV-1, HIV-2, SIV, or FIV CXCR4-specific Gp 120 sequences or Nef proteins or sequences may be delivered to the mucosa or systemically. The mucosal means of application include oral, intranasal, ocular, intravaginal, rectal, and/or intraurethral administration in liquid or particulate form. | 2008-09-18 |
20080227721 | Small peptides for the treatment of alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders - A pharmaceutical composition comprising a peptide consisting of Arg-Val-Ala-Val-Ile-Met-Gly-amide-having at least one D-amino acid. | 2008-09-18 |
20080227723 | Peptides for Preventing or Treating Liver Damage - The application of a peptide having sequence of formula I or its derivant in preparing the medicine for preventing or treating liver damage, especially liver damage and hepatitis C is disclosed, Xaa1-Gln-Xaa2-Xaa3-Thr-Ser-Gly-Xaa4 (formula I) wherein, Xaa1 is deletion, Ala,Gly,Val,Leu or Ile, Xaa2 is Thr or Ser, Xaa3 is Tyr, Phe or Trp, and Xaa4 is deletion, Ala, Gly, Val, Leu,Ile or Pro. The composite medicine containing the said peptide, its preparation method, and the polynucleotide for coding the said peptide are also disclosed. | 2008-09-18 |
20080227724 | Anti-Inflammatory Agents - The invention relates to the use of 3-aminocaprolactam derivatives for preparing a medicament intended to prevent or treat inflammatory disorders, and uses compounds of general formula (I) or a pharmaceutically acceptable salts thereof; | 2008-09-18 |
20080227725 | Cosmetic or pharmaceutical composition comprising peptides, uses and treatment processes - The present invention relates to the use of at least one peptide, with the sequence (AA)n-Arg-Gly-Ser-(AA)n, where (AA) is any amino acid or one of its derivatives, and N is an integer between 0 and 3, as an active ingredient, in or for the preparation of a cosmetic and/or dermatological and/or pharmaceutical composition. The invention also relates to its use in order to treat, inter alia, the cutaneous manifestations of aging and/or its use in order to act against cellulite. The invention is, in the same way, related to a composition containing it as well as a process of cosmetic treatment of the skin using the said peptide or the said composition. | 2008-09-18 |
20080227726 | Methods and Apparatus for Creating Particle Derivatives of HDL with Reduced Lipid Content - The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction. | 2008-09-18 |
20080227727 | Methods for enhancing the therapeutic efficacy of topoisomerase inhibitors - Disclosed are methods and compositions useful in identifying an E3 ubiquitin ligase inhibitor and modulating cell growth, comprising contacting a cell with an effective amount of an inhibitor of an E3 ubiquitin ligase, and contacting the cell with an effective amount of a topoisomerase inhibitor, wherein the treatment with the E3 ubiquitin ligase inhibitor and topoisomerase inhibitor modulates cell growth in comparison to a cell treated with the topoisomerase inhibitor alone. The present invention further provides methods for identifying and making an E3 ubiquitin ligase inhibitor. | 2008-09-18 |
20080227728 | Therapeutic Agent for the Treatment of a Condition Associated with Peripheral Vascular Disease - The present invention comprises the use of oleuropein in the preventive and/or therapeutic treatment of a condition associated to the peripheral vascular disease, particularly to venous insufficiency. | 2008-09-18 |
20080227729 | PROPHYLACTIC AND THERAPEUTIC TREATMENT OF INFECTIOUS AND OTHER DISEASES WITH IMMUNOEFFECTOR COMPOUNDS - Methods and compositions for treating or ameliorating diseases and other conditions, such as infectious diseases, autoimmune diseases and allergies are provided. The methods employ cyclic AGPs for selectively stimulating immune responses in animals and plants. | 2008-09-18 |
20080227730 | 9A-Carbamoyl and Thiocarbamoyl Azalides With Antimalarial Activity - 9a-carbamoyl and thiocarbamoyl azalides A and their pharmaceutically acceptable derivatives are useful for treatment and prevention of malaria. | 2008-09-18 |
20080227731 | BIPHENYL INHIBITORS OF CARBONYL REDUCTASE - Compositions of matter and methods of treating cancer patients may prevent or limit cardiotoxicity during or after chemotherapy, and/or may prevent or lower resistance to anthracycline drugs, both of which are believed to be caused by the human enzyme carbonyl reductase. Thus, the compositions and methods may be used to reduce the dosages of anthracycline anti-cancer drugs necessary to produce a desired cancer-cell-killing performance. Preferred embodiments comprise treating cancer patients with a pharmaceutical composition comprising biphenyl compounds having two halogenated (or pseudo-halogenated) and/or hydroxylated, aryl groups that are linked by a bridging atom. The preferred composition of biphenyl compound(s) may be administered in a pharmaceutical composition also comprising at least one anthracycline compound, or may be administered separately than the at least one anthracycline compound. Especially-preferred biphenyl compounds include triclosan, hexachlorophene, and dichlorophene. | 2008-09-18 |
20080227732 | Treatment and Control of Severe Infections Including Cystic Fibrosis - The present invention provides a pharmaceutical composition comprising antibiotic combination products for delivering two or more different antibiotics simultaneously, wherein the two different antibiotics comprise one which consisting of concentration dependent killing and the other concentration independent killing or time dependant killing activity. The invention has been worked out utilizing pharmacokinetic and pharmacodynamic principles to optimize antibiotic regimen, to improve clinical results and to potentially decrease the development of resistance. Combination of ceftazidime and tobramycin has been evolved to specifically illustrate the invention. | 2008-09-18 |
20080227733 | Method for Treating and Preventing Ischemia-Reperfusion Injury Using Rna Interfering Agent - The present invention is based, at least in part, on the discovery of methods useful in the modulation, e.g., inhibition, of gene expression or protein activity, e.g., apoptosis-related gene expression, e.g., Fas gene expression or cytokine expression, e.g., proinflammatory cytokine expression. In particular, the present invention is based on novel RNA interfering agents, e.g., siRNA in reduction, e.g., prolonged reduction, of apoptosis-related gene expression or cytokine expression in cells. Inhibition of apoptosis-related gene expression or protein activity or cytokine gene expression or protein activity, e.g. by the siRNAs used in the methods of the invention, inhibits ischemia-reperfusion injury. | 2008-09-18 |
20080227734 | Mutant Lrp5/6 Wnt-Signaling Receptors in Cancer Diagnosis, Prognosis, and Treatment - A novel mutant form of lrp5 and lrp6 genes, the mutant LRP5 and LRP6 receptor proteins expressed therefrom, and a cell line which expresses the mutant LRP5 and/or LRP6 receptor proteins. Methods of diagnosing, prognosing and treating LRP5 related diseases, specifically hyperthyroidism and parathyroid tumors, and kits suitable for rapid on-site testing. Finally, methods of screening for agents capable of modulating the mutant LRP5 or LRP6 receptor proteins and pharmaceutical compositions comprising the selected agents. | 2008-09-18 |
20080227735 | Aptamers Selected From Live Tumor Cells and the Use Thereof - The invention relates to aptamers selected from live tumor cells and to the use thereof for diagnosis and treatment of certain cancers and other pathologies. | 2008-09-18 |
20080227736 | Targeting Pseudotyped Retroviral Vectors - The present invention relates to retroviral vectors, particularly lentiviral vectors, pseudotyped with Sindbis envelope and targeted to specific cell types via a targeting moiety linked to the envelope. | 2008-09-18 |
20080227737 | Type 2 diabetes mellitus genes - Methods and compositions related to novel genes associated with type 2 diabetes mellitus. | 2008-09-18 |
20080227738 | Compositions and methods for cell dedifferentiation and tissue regeneration - The present invention provides methods and compositions to dedifferentiate a cell. The ability of the methods and compositions of the present invention to promote the dedifferentiation of differentiated cells, including terminally differentiated cells, can be used to promote regeneration of tissues and organs in vivo. The ability of the methods and compositions of the present invention to promote the dedifferentiation of differentiated cells, including terminally differentiated cells, can further be used to produce populations of stem or progenitor cells which can be used to promote regeneration of tissues and/or organs damaged by injury or disease. Accordingly, the present invention provides novel methods for the treatment of a wide range of injuries and diseases that affect many diverse cell types. | 2008-09-18 |
20080227739 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF BREAST CANCER - Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly breast cancer. | 2008-09-18 |
20080227740 | Compositions and Methods for Elimination of Unwanted Cells - Disclosed are compositions comprising a recombinant nucleic acid vector including a nucleotide sequence encoding a syncytium-inducing polypeptide expressible on a eukaryotic cell surface, and a host cell containing the recombinant vector and expressing the syncytium inducing polypeptide on its cell surface, the vectors and resultant host cells expressing the syncytium inducing polypeptide being useful for selective elimination of unwanted cells. | 2008-09-18 |
20080227741 | ZAP-70 EXPRESSION AS A MARKER FOR CHRONIC LYMPHOCYTIC LEUKEMIA / SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) - It has been surprisingly found that ZAP-70 expression, both at the protein and mRNA levels, is indicative of clinical subgroups of CLL/SLL patients. In particular, high ZAP-70 expression is indicative of Ig-unmutated CLL/SLL. Methods are provided for discriminating between clinical subgroups of CLL/SLL, by determining whether subjects overexpress ZAP-70 mRNA or protein. | 2008-09-18 |
20080227742 | Photocleavable oligonucleotide and uses thereof - This invention relates to methods and compositions of oligonucleotide constructs having a photocleavable linker. Specifically, provided herein are methods and compositions utilizing a photocleavable linker, which when exposed to light modulates the expression of genes. | 2008-09-18 |
20080227743 | Compositions and Kits for Treating Influenza - Compositions, kits and methods are provided for the treatment or prophylaxis of influenza. | 2008-09-18 |
20080227744 | BENZOFURAN DERIVED HIV PROTEASE INHIBITORS - Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided. | 2008-09-18 |
20080227745 | Methods and compositions for soluble CPG15 - Disclosed herein are compositions of soluble CPG15 and methods for treating conditions of excessive cell death, such as neurological conditions, using such compositions. Compounds that inhibit the activity of soluble CPG15 are also disclosed herein for the treatment of conditions of undesirable cell survival, such as cancer. | 2008-09-18 |
20080227746 | Methods and Compositions for Treatment of Excess Nitric Oxide or Cyanide Toxicity - Methods for treating disease states in a subject caused or exacerbated by the presence of excess nitric oxide (NO) or excess cyanide are provided. Methods for alleviating the symptoms of a disease state in a subject caused or exacerbated by the presence of excess nitric oxide (NO) or excess cyanide in the subject are also provided. Pharmaceutical compositions comprising cobinamide and a pharmaceutically acceptable carrier are also provided. | 2008-09-18 |
20080227747 | COMPOSITION AND METHODS FOR TREATING OR PREVENTING DEGENERATIVE JOINT AND CARDIOVASCULAR CONDITIONS - A therapeutic composition and methods for the treatment and prevention of a degenerative joint disorder and/or a cardiovascular disease comprising polycosanols, glucosamine and chondroitin are disclosed. | 2008-09-18 |
20080227748 | Medicament Made From Laminarine or Oligolaminarines For Treatment of Septicemia and Septic Shock - The invention relates Lo the use of laminarine, preferably in the soluble form thereof or an oligolaminarine, for the production of a medicament for treatment of septicemia and septic shock. | 2008-09-18 |
20080227749 | CARRAGEENAN-BASED FORMULATIONS AND ASSOCIATED METHODS OF USE - A method is provided for treating a female individual who suffers from or is prone to dyspareunia. The method involves vaginal and/or vulvar administration of a formulation comprising a therapeutically effective amount of a carrageenan and a pharmaceutically acceptable aqueous carrier. In addition, a carrageenan-based formulation is provided as a new composition of matter. Packaged kits for an individual to use in the administration of a carrageenan-based formulation as provided as well. | 2008-09-18 |
20080227750 | COMPOSITIONS AND METHODS FOR REGULATING RECEPTOR CLUSTERING - The invention relates to isolated complexes comprising one or more galectin associated with a Mgat5 modified glycan or polylactosamine modified glycan, and isolated lectin-Mgt5 modified glycan lattice comprising an array of mulitvalent interactions among lectins, Mgat5 modified glycans, polylactosamine modified glycans, and/or glycoproteins. Methods for evaluating a test compound for its ability to regulate receptor clustering through glycans on cell surfaces; and methods for regulating receptor clustering on cell surfaces comprising altering glycans on the cell surface associated with receptor clustering are also disclosed. | 2008-09-18 |
20080227751 | METHOD AND AGENT FOR THE PREVENTION, INHIBITION AND TREATMENT OF SEPSIS - The invention relates to the use of Asialo-G | 2008-09-18 |
20080227752 | Methods to Inhibit Histone Acetyltransferase Using Glycosaminoglycans - The present invention is directed to methods for inhibition of histone acetyltransferases using glycosaminoglycans. The invention is further directed to methods for treating disorders associated with hyperacetylation by administration of glycosaminoglycans to a patient in need thereof. In one preferred embodiment, the glycosaminoglycan is a heparin or heparan sulfate oligosaccharide. Studies show that removal of sulfate residues from the O-positions of either the uronic acid or the glucosamine did not eliminate the inhibitory activity of heparan sulfate. Since a majority of heparan sulfate binding proteins appear to require O-sulfation, molecules without certain O-sulfations can be used to inhibit HATs while not interacting with most known heparin-binding proteins. In addition, specific sequences of heparin/heparan sulfate can be used to specifically inhibit various HATs. | 2008-09-18 |
20080227753 | Nano-sized Bagasse Fiber - A new composition of nanosized bagasse fibers has been made by a method which reduces the sugarcane bagasse fibers to nano-sized particles while retaining the natural components of the bagasse. The resulting bagasse particles were shown to be effective as a nutritional supplement in a mouse model to aid in glucose control and body weight. Using the bagasse nanofibers, the addition of 5 to 10% fiber did not change the color or texture of food products. Moreover, the bagasse powder has a natural color and absorbs color evenly so that it could be used as a natural foundation material for cosmetic products. | 2008-09-18 |
20080227754 | PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES - A novel method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) | 2008-09-18 |
20080227755 | METHOD OF ADMINISTERING BISPHOSPHONATES - Bisphosphonates, in particular more potent N-bisphosphonates such as zoledronic acid and derivatives, can be used with satisfactory results for treatment of RA by intermittent administration, wherein the periods between bisphosphonate administrations are from about 2 months up to about 4 months, e.g. once every 3 months. | 2008-09-18 |
20080227756 | USE OF BISPHOSPHONATES FOR THE TREATMENT OF OSTEOGENESIS IMPERFECTA - This procedure consists in the first stage, of the administration of enough quantity of bisphosphonate preparation during the necessary period of time to acquire a degree of volumetric mineral density of the cortical tissue of application, within the normal range (average.±.1 DS). Then the administration of the bisphosphonate preparation is interrupted in order to enable the development of the sectional momentum of inertia. The length of the second stage can be determined by means of a tomography. That is to say, that the periods of administration or non-administration of the mineralizing agent are defined or controlled by precise osteologic variables and therefore are not fixed. If during the second stage the cortical mineral density drops by 6-10% of the maximum value previously obtained, administration of bishphosphonate preparation should be resumed until the corresponding maximum adjusted value is reached again. The proposed procedure of a period with bisphosphonate followed by another period without the bisphosphonate agent improves fracture resistance, provided that the length of both periods is controlled by defined osteologic variables. | 2008-09-18 |
20080227757 | Formulation for dermal application - The present invention relates to formulations on an aqueous basis with polyetherpolyol, dimethyl isosorbide, lipid and alcohol content suitable for penetration reinforcement of pharmaceutical active ingredients in the dermal application. The pharmaceutical active ingredients can be amphiphilic, zwitterionic, strongly polar or lipophilic. A preferred active ingredient is 5-aminolevulinic acid. | 2008-09-18 |
20080227758 | Nitric Oxide Releasing Prodrugs of Diaryl-2-(5h)-Furanones as Cyclooxygenase-2 Inhibitors - The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H) furanones useful in the treatment of cyclooxygenase-2 mediated diseases. | 2008-09-18 |
20080227759 | Topical composition - A composition suitable for topical application comprising a continuous phase and at least one discontinuous phase, said composition comprising at least one polyaphron dispersion, at least one vitamin D or vitamin D analogue and at least one corticosteroid. | 2008-09-18 |
20080227760 | Method of Extracting Ginsengnoside Rg2m, Pharmaceutical Composition Including Ginsengnoside Rg2, and Uses Thereof - The present invention provides a method of extracting ginsenoside Rg | 2008-09-18 |
20080227761 | METHOD OF TREATING IMMUNE PATHOLOGIES WITH LOW DOSE ESTROGEN - The invention provides a method of ameliorating a Th1-mediated immune pathology in a mammal. The method is practiced by administering a low dose of estrogen to the mammal. Optionally, an immunotherapeutic agent can also be administered to the mammal. Also provided are kits containing a low dose of estrogen and an immunotherapeutic agent. | 2008-09-18 |
20080227762 | LUPEOL ANTI-TUMOR AGENT AND USES THEREOF - The present invention provides a method of treating melanoma comprising parenterally administering to a human a therapeutically effective amount of a parenteral composition of a Lupeol-derived anti-tumor compound. | 2008-09-18 |
20080227763 | Topical hormonal composition with systemic action - The present invention relates to the area of chemotherapy and more especially to the development of new galenic forms for application to the skin. | 2008-09-18 |
20080227764 | USE OF PREGNANE-DIONES OR DIOLS AS NEUROPATHIC ANALGESIC AGENTS - The present invention relates to the use of pregnanes in inducing analgesia, preferably without overt sedation, in a mammal in response to neuropathic pain, and compositions and kits therefore. | 2008-09-18 |
20080227765 | Cytotoxic depsipeptides - Compounds of general formula (1) wherein R | 2008-09-18 |
20080227766 | Synergistic, Silver-Containing Biocide Composition - A biocidal composition comprising a combination of at least two biocidal components, in which 1,2-benzisothiazolin-3-one and/or N-methyl-1,2-benzisothiazolin-3-one and/or N-methyl-1,2-benzisothiazolin-3-one are used as one component and silver in the form of, for example, organic or inorganic silver salts, colloidal or nanoparticulate silver or silver oxide is used as the other component, has a broad spectrum of activity against diverse bacteria and fingi. | 2008-09-18 |
20080227767 | METHODS AND COMPOUNDS FOR INHIBITING AMYLOID DEPOSITS - Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid deposition, e.g., in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involve administering to a subject a therapeutic compound which inhibits IAPP-associated amyloid deposits. Accordingly, the compositions and methods of the invention are useful for inhibiting IAPP-associated amyloidosis in disorders in which such amyloid deposition occurs, such as diabetes. | 2008-09-18 |
20080227768 | Crystal of 1-Methylcarbapenem Compound - Among crystalline forms of compound (I), a 1-methylcarbapenem compound represented by the formula (I) in a crystalline form that shows main peaks in the X-ray powder diffraction pattern obtained with copper K | 2008-09-18 |
20080227769 | Compounds for the Treatment of Hepatitis C - The invention encompasses compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. | 2008-09-18 |
20080227770 | Benzoxazepine Compound - A compound represented by the formula [1]: | 2008-09-18 |
20080227771 | Delta d-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it - A δd-crystalline form of ivabradine hydrochloride of formula (I): | 2008-09-18 |
20080227772 | Diazabicyclic Aryl Derivatives as Nicotinic Acetylcholine Receptor Ligands - This invention relates to novel diazabicyclic aryl derivatives which are found to be cholinergic ligands at the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances. | 2008-09-18 |
20080227773 | Diazabicyclic Aryl Derivatives as Cholinergic Receptor Modulators - This invention relates to novel diazabicyclic aryl derivatives which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemicals substances. | 2008-09-18 |